Generate Biomedicines Inc. is a biotechnology company pioneering the field of generative biology to create breakthrough medicines. Founded by Flagship Pioneering in 2018, the company operates at the intersection of machine learning, biological engineering, and high-throughput experimental biology. Unlike traditional drug discovery, which often relies on screening existing libraries or natural molecules, Generate Biomedicines uses its proprietary 'Generate Platform' to programmatically design de novo protein therapeutics. The Generate Platform is built upon a sophisticated computational engine that has learned the fundamental principles of protein structure and function by analyzing vast datasets of biological sequences. This allows the company to design proteins with specific, desired characteristics—such as binding affinity, stability, and potency—across various modalities, including antibodies, peptides, and enzymes. By treating drug discovery as an engineering challenge, the company aims to increase the probability of clinical success and drastically shorten development timelines. Generate Biomedicines' therapeutic pipeline spans multiple high-impact areas, including oncology, immunology, and infectious diseases. The company is led by CEO Mike Nally and a team of experts in both computational science and drug development. Through its innovative approach, Generate Biomedicines seeks to transform the pharmaceutical industry by moving from a model of serendipitous discovery to one of intentional, AI-driven design, ultimately delivering more effective treatments to patients worldwide.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!